Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Brain glioma treatment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was largely unsuccessful due to their inability to cross blood–brain barrier (BBB). Here we describe targeted nanoscale immunoconjugates (NICs) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Galstyan, Anna, Markman, Janet L., Shatalova, Ekaterina S., Chiechi, Antonella, Korman, Alan J., Patil, Rameshwar, Klymyshyn, Dmytro, Tourtellotte, Warren G., Israel, Liron L., Braubach, Oliver, Ljubimov, Vladimir A., Mashouf, Leila A., Ramesh, Arshia, Grodzinski, Zachary B., Penichet, Manuel L., Black, Keith L., Holler, Eggehard, Sun, Tao, Ding, Hui, Ljubimov, Alexander V., Ljubimova, Julia Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713723/
https://www.ncbi.nlm.nih.gov/pubmed/31462642
http://dx.doi.org/10.1038/s41467-019-11719-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713723/
https://www.ncbi.nlm.nih.gov/pubmed/31462642
http://dx.doi.org/10.1038/s41467-019-11719-3

Ejemplares similares